Titlebook: Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology; Scientific and Clini M. R. Nowrousian Book 20021st edition Springer-Verlag/W

neutrophils

不适当

Relationship between anemia and tumor hypoxia, satisfy the oxygen demand (Vaupel et al. 1989). The complex pathophysiological mechanisms have recently been reviewed (Höckel and Vaupel 2001). Hypoxia seems to represent a general pathophysiological phenomenon in solid cancers and is associated with more rapid malignant progression and poor prognosis (Höckel et al. 1996; Höckel and Vaupel 2001).

财产

curettage

M. R. NowrousianComprehensive presentation of anemia in cancer and its treatment.Assessment of current and potential applications of erythopoietin.Presented by world experts in the field

Vldl379

Prevalence, pathophysiology, predictive factors, and prognostic significance of anemia in cancer chusually worsens during radiotherapy and chemotherapy, and in a considerable number of patients, radiotherapy and chemotherapy as such produce anemia, primarily due to their myelosuppressive effect (Tables 1–3) (Skillings et al. 1993; Estrin et al. 1999; Groopman and Itri 1999; Lammering et al. 1999;

遭遇

Red blood cell transfusion, risks and limitations,ll be undetectable even with the most sensitive screening tests. Moreover it is necessary to define, together with the risk of transfusion transmitted infections, the nature and magnitude of all the other potential risk of blood transfusion such as the immunological risks and circulatory and metabol

后退

你不公正

rhEPO in anemia associated with solid tumors and chemotherapy, multiple transfusions (Barrett-Lee et al. 2000). The mean proportion of patients with Hb levels less than 11 g/dl rose from 17% before the first cycle, to 38% by the sixth, despite the transfusions in 33% of patients. In a recent comprehensive review of chemotherapy trials, the incidence of anemia

不来

老巫婆

rhEPO in hematopoietic stem cell mobilization, transplantation and in-vitro expansion,hEPO) has been established as a treatment for renal anemia it has been of interest whether treatment may be of benefit in the transplantation setting. So far data do . support any transfusional benefits with the use of rhEPO after autologous transplantation. In patients receiving an allograft, espec